ALDX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 112286 min ago

@ $3.36

Išleistas: 14 vas. 2024 @ 20:54

Grąža: 24.59%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 4.19 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:17):

Stats
Šios dienos apimtis	182 310
Vidutinė apimtis	580 245
Rinkos kapitalizacija	248.35M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $-0.110 ) 2024-06-04
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.53
ATR14	$0.00600 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-12	Machatha Stephen	Sell	11 537	Common Stock
2024-03-11	Greenberg Bruce	Sell	13 201	Common Stock
2024-04-05	Perceptive Advisors Llc	Buy	37 712	Common Stock
2024-04-04	Perceptive Advisors Llc	Buy	140 281	Common Stock
2024-04-03	Perceptive Advisors Llc	Buy	309 847	Common Stock

INSIDER POWER
17.28
Last 100 transactions
Buy: 8 132 048 \| Sell: 3 580 213

Tūris Koreliacija

Ilgas: 0.09 (neutral)

Trumpas: 0.35 (neutral)

Signal:(39.183) Neutral

Aldeyra Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVVC	0.96
BOCH	0.96
ACCD	0.956
VORB	0.955
AEZS	0.955
VIAV	0.955
PHCF	0.954
LMDX	0.954
NEOG	0.952
CTHR	0.952

10 Labiausiai neigiamai susiję koreliacijos
ORTX	-0.975
DLHC	-0.959
ISTR	-0.957
RETA	-0.953
THRN	-0.953
ESSA	-0.949
FRBK	-0.948
FMIV	-0.946
INO	-0.945
DAWN	-0.944

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aldeyra Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.74
( moderate negative )

-0.66
( moderate negative )

0.00
( neutral )

0.47
( neutral )

0.38
( neutral )

Aldeyra Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-262 780 (0.00 %)
EPS:	$-0.640

FY	2023
Pajamos:	$0
Bruto pelnas:	$-262 780 (0.00 %)
EPS:	$-0.640

FY	2022
Pajamos:	$0
Bruto pelnas:	$-258 707 (0.00 %)
EPS:	$-1.050

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.070

Financial Reports:

No articles found.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Realaus laiko atnaujinimai Aldeyra Therapeutics Inc [ALDX]

Upcoming Earnings Alert